- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03137862
"Gluten Friendly" Treatment in Celiac Disease (GLUFR)
A Prospective, Double Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a "Gluten Friendly" Bread in Population With Celiac Disease
Study Overview
Status
Conditions
Detailed Description
Background: Gluten ingestion leads to small intestinal mucosal injury in patients with celiac disease (CD), necessitating rigid, life-long exclusion of gluten from diet. Current therapies based on gluten-free dietary regimes, are also impairing social life, increased expenses for gluten free products, personal dissatisfaction and frustration. In addition, gluten-free products often have a low content of vitamins, such as vitamins B, ions such as calcium, iron, zinc and magnesium, as well of fibres. An alternative to the exclusion of gluten from diet may be the detoxification of gluten without affecting the technological performance of the flour and dough. Recently, we succeeded in developing a new and innovative method to detoxify gluten proteins from cereal grains: the modified stuff was capable to retain nutritional and technological properties of wheat proteins, and proved to be safe to celiac and gluten-sensitive patients. This innovation is usually referred to as "gluten friendly".
Objective: To establish the efficacy and safety of a prolonged exposure to the "Gluten Friendly trademark (™)" bread in patients with celiac disease.
Design: A prospective, double-blind, placebo-controlled, randomized trial to be conducted on adults with biopsy-proven CD who were being treated with a gluten-free diet (GFD) for >2 years. Before enrollment, consenting patients will have to sign an informed consent form with full details of the aims of the study, and an explanation of the experimental procedures of the study. At the baseline evaluation (t 0 ), patients will undergo a clinical examination, an upper gastrointestinal endoscopy for the histologic evaluation of the duodenal mucosa, and a blood drawing for routine chemistry and anti-transglutaminase (ATGA) and anti-endomysium (EMA) antibodies checking. Eligible to be enrolled into the study will be patients with undetectable ATGA and EMA antibodies. They will be randomly assigned to one of three experimental regimens:
- the control arm: patients will maintain a commercially available GFD and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls (Group A)
- the innovative arm 1: patients will be have to continue the GFD supplemented with 3 gr of "gluten friendly"™ bread daily for 12 weeks (Group B)
- the innovative arm 2: patients will be have to continue the GFD supplemented with 6 gr of "gluten friendly"™ bread daily for 12 weeks (group C).
All patients will be provided with a diary card to monitor their adherence to the assigned treatments and to register their acceptance of the experimental breads. Either patients and attending physicians will maintain blindness about the treatment assignment throughout t the study period.
At the end of the 2nd and 4th treatment week, patients will be monitored for ATGA and EMA antibodies, and those with positive results will undergo a repeat endoscopy for checking the integrity of the duodenal mucosa: in the event of any deterioration of histology, patients will patients will be considered as treatment failures. Patients with negative serology will be kept on treatment for the scheduled 12 weeks. At 12th week, patients will have to return for a clinical examination, a repeat blood drawing for ATGA, anti-EMA, anti-gliadin (AGA both IgG and IgA) antibodies checking, immunoglobulin G (IgG), immunoglobulin A (IgA), routine chemistry, complete hematology work up including serum iron, phosphorus, folate, and vitamin D3 measurements. In addition, a new, repeat endoscopy will be scheduled for all enrolled patients with the intent to acquire information on the histologic status of the duodenal mucosa, the the principal outcome of this investigation. After the completion of the 12 weeks study period, all patients will be invited to enter in an open study in which the addition of the "Gluten Friendly ™" bread to their GFD diet will be administered for a very long period of time, likely 6 or 12 months. This section of the study will be run on a voluntary basis and will serve to gain information about safety of the modified gluten in the long run.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
FG
-
San Giovanni Rotondo, FG, Italy, 71013
- Angelo Andriulli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- celiac patients with positive antitransglutaminase and histology compatible with celiac disease
Exclusion Criteria:
- positive antitransglutaminase at enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Arm A comparator
Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
|
patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
|
EXPERIMENTAL: Arm B
Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of "gluten friendly" bread daily for 12 weeks.
|
patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
patients will have to continue the GFD supplemented with 3 gr of "gluten friendly" bread daily for 12 weeks
|
EXPERIMENTAL: Arm C
Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of "gluten friendly" bread daily for 12 weeks
|
patients will have to continue the GFD supplemented with 6 gr of "gluten friendly" bread daily for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of small bowel mucosal density and evaluation of the serologic markers of celiac disease
Time Frame: Three months after of treatment
|
Endoscopy evaluation of duodenum and determination of anti-tTG2-IgA, EMA and AGA antibodies levels
|
Three months after of treatment
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT64/CE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
University of PalermoCompletedNot-celiac Gluten (Wheat) SensitivityItaly
-
University of PalermoRecruiting
-
University of PalermoCompletedNot-celiac Gluten SensitivityItaly
-
ASST Fatebenefratelli SaccoNot yet recruiting
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitationCeliac Disease in ChildrenNetherlands
Clinical Trials on Gluten free bread
-
Oy Karl Fazer AbCompletedIrritable Bowel Syndrome | Wheat SensitivityFinland
-
TC Erciyes UniversityCompleted
-
University of BariCompletedIrritable Bowel Syndrome | Gluten Sensitivity
-
University of RoehamptonTerminated
-
University of Southern DenmarkOdense University Hospital; University Hospital Bispebjerg and Frederiksberg; Hospital of Southern Jutland and other collaboratorsNot yet recruitingInflammatory Bowel Diseases | Ulcerative ColitisDenmark
-
Massachusetts General HospitalTerminated
-
University Hospital, Clermont-FerrandCentre de Recherche en Nutrition Humaine d'Auvergne; Institut National de Recherche... and other collaboratorsCompleted
-
Göteborg UniversitySahlgrenska University Hospital, Sweden; University of Skövde; Ekhaga foundationRecruitingDiabetes | Celiac Disease | Metabolic Disease | AutoimmunitySweden
-
Università degli Studi di BresciaUnknownNon Celiac Gluten SensitivityItaly
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden